Sanofi (NASDAQ:SNY) Shares Bought by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. raised its position in Sanofi (NASDAQ:SNY) by 25.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 360,282 shares of the company’s stock after buying an additional 72,065 shares during the period. Rockefeller Capital Management L.P.’s holdings in Sanofi were worth $20,758,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of SNY. Stablepoint Partners LLC grew its stake in Sanofi by 0.8% in the 3rd quarter. Stablepoint Partners LLC now owns 23,893 shares of the company’s stock valued at $1,377,000 after acquiring an additional 189 shares during the period. PDS Planning Inc grew its position in shares of Sanofi by 3.1% in the third quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock valued at $383,000 after purchasing an additional 200 shares during the period. Eagle Ridge Investment Management increased its stake in shares of Sanofi by 3.8% during the third quarter. Eagle Ridge Investment Management now owns 5,571 shares of the company’s stock worth $321,000 after purchasing an additional 203 shares in the last quarter. Financial Advocates Investment Management raised its position in shares of Sanofi by 3.4% during the 3rd quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock worth $365,000 after purchasing an additional 206 shares during the last quarter. Finally, Angeles Investment Advisors LLC lifted its stake in Sanofi by 1.9% in the 3rd quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company’s stock valued at $653,000 after buying an additional 210 shares in the last quarter. 10.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Price Performance

SNY stock opened at $48.49 on Monday. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The firm has a market capitalization of $123.06 billion, a PE ratio of 24.74, a price-to-earnings-growth ratio of 1.23 and a beta of 0.61. The business has a 50 day simple moving average of $52.80 and a 200-day simple moving average of $52.15.

Sanofi (NASDAQ:SNY) last issued its earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. During the same period in the prior year, the business earned $2.55 EPS. The firm’s quarterly revenue was up 12.3% on a year-over-year basis. Equities research analysts anticipate that Sanofi will post 4.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 7th. Citigroup raised Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.